GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioNxt Solutions Inc (XCNQ:BNXT) » Definitions » Debt-to-EBITDA

BioNxt Solutions (XCNQ:BNXT) Debt-to-EBITDA : -0.57 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is BioNxt Solutions Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioNxt Solutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$4.89 Mil. BioNxt Solutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. BioNxt Solutions's annualized EBITDA for the quarter that ended in Dec. 2023 was C$-8.62 Mil. BioNxt Solutions's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioNxt Solutions's Debt-to-EBITDA or its related term are showing as below:

XCNQ:BNXT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.1   Med: -0.33   Max: -0.21
Current: -1.1

During the past 6 years, the highest Debt-to-EBITDA Ratio of BioNxt Solutions was -0.21. The lowest was -1.10. And the median was -0.33.

XCNQ:BNXT's Debt-to-EBITDA is ranked worse than
100% of 658 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs XCNQ:BNXT: -1.10

BioNxt Solutions Debt-to-EBITDA Historical Data

The historical data trend for BioNxt Solutions's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNxt Solutions Debt-to-EBITDA Chart

BioNxt Solutions Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.21 -0.21 -0.28 -0.38 -0.76

BioNxt Solutions Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -0.15 -0.96 -1.13 -0.57

Competitive Comparison of BioNxt Solutions's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, BioNxt Solutions's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNxt Solutions's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioNxt Solutions's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioNxt Solutions's Debt-to-EBITDA falls into.



BioNxt Solutions Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioNxt Solutions's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.894 + 0) / -6.485
=-0.75

BioNxt Solutions's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.894 + 0) / -8.624
=-0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


BioNxt Solutions  (XCNQ:BNXT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioNxt Solutions Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioNxt Solutions's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNxt Solutions (XCNQ:BNXT) Business Description

Traded in Other Exchanges
Address
1820 Fir Street, Suite 270, Vancouver, BC, CAN, V6J 3B1
BioNxt Solutions Inc is a cannabis company engaged in developing analytical testing, processing, and formulation capability in Canada. It is also engaged in research, cultivation, extraction, import, distribution, and manufacturing in Germany. The products of the company include Drug Delivery, Point-of-Care Diagnostics, and Psychedelics.

BioNxt Solutions (XCNQ:BNXT) Headlines

No Headlines